| Literature DB >> 33558843 |
Wei Zhang1, Caiping Zhang1, Yifang Bi1, Lirong Yuan1, Yi Jiang1, Chaolu Hasi1, Xinri Zhang1, Xiaomei Kong1.
Abstract
OBJECTIVE: It aimed to analyze the epidemic situation of new coronary pneumonia (COVID-19) based on the epidemiological Markov model, and to study the clinical risk factors of the patients based on the patient's cardinal data and clinical symptoms.Entities:
Keywords: COVID-19; Clinical manifestations; Epidemiology; Markov model
Year: 2021 PMID: 33558843 PMCID: PMC7857990 DOI: 10.1016/j.rinp.2021.103881
Source DB: PubMed Journal: Results Phys ISSN: 2211-3797 Impact factor: 4.476
Fig. 1Process of research plan.
Fig. 2The development process of COVID-19 pneumonia.
Case distribution of COVID-19 patients from state N to state M.
| State 1 | State 4 | Total | |||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||
| 1 | 78 | 67 | 5 | 9 | 159 |
| 2 | 132 | 27 | 17 | 176 | |
| 39 | 63 | 102 | |||
| 4 | 63 | ||||
| Total | 500 | ||||
Parameter estimation results.
| State | Transfer density | Average length of stay (days) | Median time (days) |
|---|---|---|---|
| 1 | 5.5461 | 2.14 | 0.26 |
| 2 | 0.1372 | 5.22 | 6.13 |
| 3 | 0.5764 | 6.64 | 1.05 |
Fig. 3Parameter estimation results. (State 1: early stage of infection; State 2: acute stage of infection; State 3: early stage of COVID-19.)
Comparison of baseline data between the two groups of patients.
| Symptoms/Group | General group (n = 200) | Acute critical group (n = 300) | |
|---|---|---|---|
| Male | 82 (41%) | 186 (62%) | |
| Female | 118 (59%) | 114 (38%) | |
| Age/years old | 22.59 ± 2.61 | 52.66 ± 14.42 | |
| Smoking | 7 (3.5%) | 5 (2.5%) | |
| Drinking | 5 (1.7%) | 3 (1%) | |
| Tuberculosis | 2 (1%) | 1 (0.3%) | |
| Chronic obstructive tuberculosis | 10 (5%) | 6 (2%) | |
| Hypertension | 52 (26%) | 101 (33.7%) | |
| Coronary heart disease | 28 (14%) | 58 (19.3%) | |
| Arrhythmia | 13 (6.5%) | 9 (3%) | |
| Gallbladder disease | 8 (4%) | 2 (0.7%) | |
| Gastrointestinal disease | 22 (11%) | 18 (6%) | |
| Liver disease | 11 (5.5%) | 5 (1.7%) | |
| Cancer | 14 (7%) | 8 (2.7%) | |
| Diabetes | 62 (31%) | 81 (27%) | |
| Thyroid disease | 15 (7.5%) | 18 (6%) | |
Fig. 4Male to female ratio. (A: general group; B acute critical group.)
Fig. 5Summary of single factors of patient clinical outcomes. (Note: A: hypertension B: coronary heart disease C: shortness of breath D: myocardial damage E: thrombocytopenia.)
Comparison of clinical symptoms between the two groups of patients (n (%)).
| Symptoms/Group | General group (n = 200) | Acute critical group (n = 300) | |
|---|---|---|---|
| Fever | 83 (91.5%) | 256 (85.3%) | |
| Cold fear | 53 (26.5%) | 77 (25.7%) | |
| Headache | 17 (8.5%) | 15 (5%) | |
| Myalgia | 33 (16.5%) | 46 (15.3%) | |
| Sore throat | 17 (8.5%) | 39 (13%) | |
| Dry cough | 15 (7.5%) | 18 (6%) | |
| Expectoration | 43 (21.5%) | 59 (19.7%) | |
| Chest uncomfortable | 89 (44.5%) | 97 (32.3%) | |
| Shortness of breath | 31 (15.5%) | 96 (32%) | |
| Chest pain | 9 (4.5%) | 13 (4.3%) | |
| Stomach ache | 1 (0.5%) | 1 (0.3%) | |
| Diarrhea | 53 (26.5%) | 74 (24.7%) | |
| Complications | 8 (4%) | 54 (18%) | |
| Myocardial damage | 11 (5.5%) | 43 (14.3%) | |
| Thrombocytopenia | 13 (6.5%) | 16 (5.3%) | |
| Liver insufficiency | 9 (4.5%) | 10 (3.3%) | |
| Renal insufficiency | |||
Multivariate analysis of clinical risk for COVID-19 patients.
| Factors | ||||||
|---|---|---|---|---|---|---|
| Gender | 1.341 | 0.431 | 5.024 | 0.002 | 3.823 | 1.643–8.897 |
| Age | 0.618 | 0.278 | 4.048 | 0.026 | 1.855 | 1.076–3.199 |
| Hypertension | 1.627 | 0.621 | 7.055 | 0.009 | 5.089 | 1.507–17.187 |
| Coronary heart disease | 1.171 | 0.451 | 5.135 | 0.009 | 3.225 | 1.332–7.807 |
| Shortness of breath | 1.124 | 0.321 | 4.353 | 0.000 | 3.077 | 1.640–5.773 |
| Myocardial damage | 1.625 | 0.652 | 6.312 | 0.013 | 5.078 | 1.415–18.227 |
| Thrombocytopenia | 2.156 | 0.323 | 7.421 | 0.002 | 3.9973.997 | 1.363–34.4271.363–34.427 |
Fig. 6ROC curve for predicting the deterioration of clinical patients.